Area of research
Hematology · Genetics
Research interest
Research interests include Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Platelet Disorders and Treatments, and Acute Myeloid Leukemia Research.
Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Deep learning applications in visual data for benign and malignant hematologic conditions: a systematic review and visual glossary
Data from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Data from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
Improving Augmented Human Intelligence to Distinguish Burkitt Lymphoma From Diffuse Large B-Cell Lymphoma Cases
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis
The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment
Germline Lysine-Specific Demethylase 1 ( <i>LSD1/KDM1A</i> ) Mutations Confer Susceptibility to Multiple Myeloma
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study
Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk
Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Digital image analysis agrees with visual estimates of adult bone marrow trephine biopsy cellularity
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Clinical utility of next‐generation sequencing in the diagnosis of hereditary haemolytic anaemias
Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy